LRRK2 and Parkinson disease: In human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons from PD patients carrying mutations in GBA, LRRK2, DJ-1 or PARKIN, it was found that S-181 reduced β-GCase activity.